Arcus Biosciences Inc. (NASDAQ: RCUS) Chief Accounting Officer Alexander Azoy sold 2,827 shares of common stock for $84,810 on August 21, 2026, under a prearranged Rule 10b5-1 trading plan.
The transaction followed the exercise of stock options to acquire the same number of shares at $15.44 per share, totaling $43,648. Azoy’s direct holdings in the company remain at 39,581 shares, including unvested restricted stock units, while he holds 3,073 exercisable options vesting in equal monthly installments through January 2028.
Arcus Biosciences’ stock closed at $30 on the day of the sale, near its 52-week high of $31.73. The company’s shares have risen 186% over the past year, though InvestingPro analysis indicates the stock may be slightly overvalued relative to its fair value estimate. Four analysts have revised earnings estimates upward for the upcoming period.
In the second quarter of 2026, Arcus Biosciences reported adjusted earnings per share of -$0.72, beating the forecasted -$0.90, and revenue of $41 million, more than double the expected $22.22 million. The company’s cash position is projected to extend into at least the second half of 2028.
